Taysha Gene Therapies, Inc. (TSHA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TSHA currently has 287M outstanding shares. with significant dilution risk as 237M authorized shares could dilute existing holders by 82.4%. The company has significantly diluted shareholders by 37.25% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 287.4M shares outstanding |
290M | 240M |
| Mar 19, 2026 |
10-K filing | 287.3M shares outstanding |
290M | 240M |
| Nov 04, 2025 |
10-Q filing | 273.9M shares outstanding |
270M | 240M |
| May 15, 2025 |
10-Q filing | 214.7M shares outstanding |
210M | 240M |
| Feb 26, 2025 |
10-K filing | 205.0M shares outstanding |
210M | 240M |
| Dec 13, 2024 |
S-3 filing: The company files an S-3 to offer shares of common stock, preferred stock, debt securities and warrants up to an aggregate amount of $300,000,000. |
200M | 240M |
| Nov 13, 2024 |
10-Q filing | 204.9M shares outstanding |
200M | 190M |
| Aug 12, 2024 |
10-Q filing | 204.9M shares outstanding |
200M | 190M |
| May 14, 2024 |
10-Q filing | 187.0M shares outstanding |
190M | 190M |
| Mar 19, 2024 |
10-K filing | 187.0M shares outstanding |
190M | 190M |
| Nov 14, 2023 |
10-Q filing | 187.0M shares outstanding |
190M | 190M |
| Aug 30, 2023 |
S-3 filing: This prospectus relates to the proposed resale from time to time of up to 166,663,354 shares of common stock by the selling stockholders. |
64M | 190M |
| Aug 14, 2023 |
10-Q filing | 64.2M shares outstanding |
64M | 26M |
| May 11, 2023 |
10-Q filing | 63.3M shares outstanding |
63M | 26M |
| Apr 05, 2023 |
S-3 filing: This is an S-3 filing related to the registration of common stock for sale by selling stockholders. The company will not receive any proceeds from this offering. |
63M | 26M |
| Mar 28, 2023 |
10-K filing | 63.5M shares outstanding |
63M | 26M |
| Nov 08, 2022 |
10-Q filing | 62.4M shares outstanding |
62M | 26M |
| Aug 11, 2022 |
10-Q filing | 40.1M shares outstanding |
40M | 26M |
| May 16, 2022 |
10-Q filing | 40.5M shares outstanding |
41M | 26M |
| Mar 31, 2022 |
10-K filing | 38.5M shares outstanding |
38M | 26M |
| Nov 10, 2021 |
10-Q filing | 38.5M shares outstanding |
38M | 26M |
| Oct 05, 2021 |
S-3 filing: The company is filing an S-3 to offer and sell up to $350,000,000 of any combination of common stock, preferred stock, and debt securities from time to time. |
38M | 26M |
| Aug 16, 2021 |
10-Q filing | 38.4M shares outstanding |
38M | 7.6M |
| May 11, 2021 |
10-Q filing | 37.9M shares outstanding |
38M | 7.6M |
| Mar 03, 2021 |
10-K filing | 37.8M shares outstanding |
38M | 7.6M |
| Nov 12, 2020 |
10-Q filing | 37.8M shares outstanding |
38M | 7.6M |
| Sep 18, 2020 |
S-1/A filing: The document is an S-1/A filing for an initial public offering of common stock. It includes details on voting rights, liquidation preferences, the offering itself (number of shares, price, use of proceeds), a directed share program, risk factors, and the proposed Nasdaq Global Market symbol. |
35M | 7.6M |
| Sep 17, 2020 |
S-1/A filing: This is an S-1/A filing for Taysha Gene Therapies, Inc. The company is offering 6,578,950 shares of common stock, with an underwriter option to purchase an additional 986,842 shares, with a use of proceeds to fund discovery and IND-enabling activities, as well as manufacturing and quality control testing for clinical and preclinical programs, clinical trial, regulatory and medical activities for TSHA-101, TSHA-102, TSHA-103, TSHA-104 and TSHA-118 and the establishment of in-house manufacturing. |
35M | 7.6M |
| Sep 02, 2020 |
S-1 filing: This is an initial public offering of common stock. The document provides information about the number of shares to be offered, potential use of proceeds, and risk factors associated with investing in the company's stock. |
26M | 0 |